Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases

被引：23

作者：

Florez-Alvarez, Lizdany ^{[1
,2
]}

Ruiz-Perez, Lanie ^{[3
]}

Taborda, Natalia ^{[2
,4
]}

Hernandez, Juan C. ^{[1
]}

机构：

[1] Univ Cooperat Colombia, Fac Med, Infettare, Medellin, Colombia

[2] Univ Antioquia, Fac Med, Grp Inmunovirol, Calle 70 52-21, Medellin, Colombia

[3] Curtin Univ, Sch Pharm & Biomed Sci, Curtin Hlth Innovat Res Inst, GPO Box U1987, Perth, WA 6845, Australia

[4] Corp Univ Remington, Fac Ciencias Salud, Programa Med, Grp Invest Biomed Uniremington, Medellin, Colombia

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 05期

关键词：

cancer; immune modulators; infectious diseases; inflammation; Toll-like receptors; vaccines; PHASE-I; ULCERATIVE-COLITIS; CLINICAL-OUTCOMES; IMMUNE-RESPONSE; BREAST-CANCER; TLR9; AGONIST; POLYMORPHISMS; SUSCEPTIBILITY; INNATE; ASSOCIATION;

D O I：

10.2217/imt-2019-0096

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Toll-like receptors (TLRs) are widely expressed pattern recognition receptors that bind to conserved molecular patterns expressed by pathogens and damaged cells. After recognition, activated TLRs induce the expression of various proinflammatory and antiviral molecules. Thus, TLRs are potential targets for treatment strategies aimed at boosting the adaptive immune response to vaccines, controlling infections, enhancing immune responses during tumor treatment and attenuating immune responses in inflammatory disorders. This Special Report examines the potential of TLRs as targets for the treatment of cancer, infections and inflammatory diseases. Here, we make a particular emphasis on molecules capable of modulating TLRs and their therapeutic applications.

引用

页码：311 / 322

页数：12

共 111 条

[61] A TLR6 polymorphism is associated with increased risk of Legionnaires' disease [J].

Misch, E. A. ;

Verbon, A. ;

Prins, J. M. ;

Skerrett, S. J. ;

Hawn, T. R. .

GENES AND IMMUNITY, 2013, 14 (07) :420-426

[62] Toll-like receptor polymorphisms and susceptibility to human disease [J].

Misch, E. Ann ;

Hawn, Thomas R. .

CLINICAL SCIENCE, 2008, 114 (5-6) :347-360

[63] Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models [J].

Miyauchi, Masanori ;

Murata, Masashi ;

Fukushima, Akihisa ;

Sato, Toshiyuki ;

Nakagawa, Masae ;

Fujii, Tetsuya ;

Koseki, Norimasa ;

Chiba, Nobuyuki ;

Kashiwazaki, Yasuo .

DRUG DISCOVERIES AND THERAPEUTICS, 2012, 6 (04) :218-225

[64] Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses [J].

Mogensen, Trine H. .

CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (02) :240-+

[65] Vaccination in early life: standing up to the challenges [J].

Mohr, Elodie ;

Siegrist, Claire-Anne .

CURRENT OPINION IN IMMUNOLOGY, 2016, 41 :1-8

[66] Evidence of NI-0101 Pharmacological Activity, an Anti-TLR4 Antibody, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Receiving LPS [J].

Monnet, E. ;

Lapeyre, G. ;

van Poelgeest, E. ;

Jacqmin, P. ;

de Graaf, K. ;

Reijers, J. ;

Moerland, M. ;

Burggraaf, J. ;

de Min, C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) :200-208

[67] Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells [J].

Napolitani, G ;

Rinaldi, A ;

Bertoni, F ;

Sallusto, F ;

Lanzavecchia, A .

NATURE IMMUNOLOGY, 2005, 6 (08) :769-776

[68] Implication of Activated Astrocytes in the Development of Drug Dependence Differences between Methamphetamine and Morphine [J].

Narita, Minoru ;

Suzuki, Masami ;

Kuzumaki, Naoko ;

Miyatake, Mayumi ;

Suzuki, Tsutomu .

ADDICTION REVIEWS 2008, 2008, 1141 :96-104

[69] Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3. [J].

Okazaki, Satoshi ;

Stintzing, Sebastian ;

Heinemann, Volker ;

Cao, Shu ;

Zhang, Wu ;

Yang, Dongyun ;

Ning, Yan ;

Matsusaka, Satoshi ;

Berger, Martin D. ;

West, Jordan D. ;

Miyamoto, Yuji ;

Suenaga, Mitsukuni ;

Lenz, Heinz-Josef .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)

[70] Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis The ACCESS Randomized Trial [J].

Opal, Steven M. ;

Laterre, Pierre-Francois ;

Francois, Bruno ;

LaRosa, Steven P. ;

Angus, Derek C. ;

Mira, Jean-Paul ;

Wittebole, Xavier ;

Dugernier, Thierry ;

Perrotin, Dominique ;

Tidswell, Mark ;

Jauregui, Luis ;

Krell, Kenneth ;

Pachl, Jan ;

Takahashi, Takeshi ;

Peckelsen, Claus ;

Cordasco, Edward ;

Chang, Chia-Sheng ;

Oeyen, Sandra ;

Aikawa, Naoki ;

Maruyama, Tatsuya ;

Schein, Roland ;

Kalil, Andre C. ;

Van Nuffelen, Marc ;

Lynn, Melvyn ;

Rossignol, Daniel P. ;

Gogate, Jogadish ;

Roberts, Mary B. ;

Wheeler, Janice L. ;

Vincent, Jean-Louis .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (11) :1154-1162

← 2 3 4 5 6 7 8 9 10 11 →